U.S. Office-based Labs Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
U.S. Office-Based Labs Market size was valued at USD 11.2 billion in 2023 and is estimated to grow at a CAGR of 7.6% during the forecast period to reach USD 21 billion by 2032. An office-based labs (OBLs) refers to a medical facility located within a physician’s office or clinic that is equipped to perform diagnostic and therapeutic procedures on-site.
These labs are designed to provide convenient access to medical services for patients while allowing physicians to maintain greater control over the diagnostic process and treatment plans. The increasing prevalence of target diseases, such as chronic kidney disease, deep vein thrombosis, and venous insufficiency, has emerged as a significant driver for the market. For instance, according to the Centers for Disease Control and Prevention (CDC), approximately 35.5 million adults were affected by chronic kidney disease (CKD) in the U.S.
Furthermore, growing advancements in medical technology have expanded the capabilities of performing a diverse array of diagnostic tests and treatments within office-based settings. The increasing adoption of endovascular treatment devices for various procedures, coupled with other contributing factors.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
U.S. Office-Based Labs Market Size in 2023: | USD 11.2 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 7.6 |
2023 Value Projection: | USD 21 Billion |
Historical Data for: | 2018 – 2023 |
No of Pages: | 75 |
Tables, Charts & Figures: | 57 |
Segments Covered: | Modality, Service, and Specialist |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The increasing approval of endovascular procedures in office-based labs indicates a shift towards more accessible, cost-effective, and patient-centred vascular care, providing minimally invasive treatments with enhanced convenience and outcomes.
Based on modality, the market is classified into single-specialty labs, multi-specialty labs and hybrid labs. The single speciality labs segment held a market size of 4.7 billion in 2023.
Based on service, the U.S. office-based labs market is bifurcated into peripheral vascular intervention, endovascular interventions, cardiac services, interventional radiology, venous services, and other services. The peripheral vascular intervention is estimated to account for a market size of USD 6.3 billion by the end of 2032.
Based on specialists, the U.S. office-based labs market is segmented into vascular surgeons, interventional, cardiologist, interventional radiologists, and other specialists. The vascular surgeons held a market share of 32.6% in the forecast period.
U.S. office-based labs market accounted for USD 11.2 billion revenue in 2023 and is predicted to witness substantial industry progression over the analysis timeline.
The U.S. office-based labs industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced devices based on different technologies is among a key market strategy. Some of the leading industry players including Siemens Healthineers AG, Abbott Laboratories, Koninklijke Philips N.V, among others have a notable presence in the market.
Some of the eminent market participants operating in the U.S. office-based labs industry include:
Market, By Modality
Market, By Service
Market, By Speciality
Some of the leading U.S. office-based labs industry players are Koninklijke Philips N.V, GE Healthcare, Siemens Healthineers AG, Medtronic Plc, Boston Scientific Corporation, Abbott Laboratories, Cardiovascular Systems, Inc., Envision Healthcare, Surgery Care Associates, Inc., Surgery Partners, National Cardiovascular Partners, and TH Medical.
The single specialty labs segment generated USD 4.7 billion in 2023 and is set to gain significant traction through 2032 as these labs offer cost-efficient solutions, patient-centric approaches, innovation opportunities, and enhanced referral networks.
U.S. office-based labs industry was USD 11.2 billion in revenue in 2023 and is estimated to expand at 7.6% CAGR during 2024-2032 driven by the growing demand by medical service providers due to the increasing prevalence of target diseases.
The peripheral vascular intervention segment is estimated to reach USD 6.3 billion in revenue by 2032 owing to its increasing adoption for managing the treatment of peripheral arterial disease (PAD) across the region.